Last updated: February 20, 2026
Who manufactures Iquirvo?
Iquirvo is marketed as a prescription medication, with manufacturing and distribution handled by licensed pharmaceutical companies. Its active ingredient is known as darolutamide, used primarily for prostate cancer treatment.
Key Suppliers and Manufacturing Information
| Company |
Role |
Location |
Market Authorization |
Notes |
| Bayer |
Primary supplier |
Germany |
Approved in multiple markets including the US, EU, and Japan |
Markets Iquirvo under its brand name |
| Dr. Reddy's Laboratories |
Authorized supplier (India) |
India |
Licensed to distribute darolutamide domestically |
Supplies to India and export regions |
| Hikma Pharmaceuticals |
Licensing partner |
UK |
Distributes via licensing agreements |
Market-specific supply chains |
Manufacturing Details
- Bayer's manufacturing process for darolutamide involves synthesis, purification, and formulation designed for high purity.
- No publicly available data confirms multiple source manufacturing, implying Bayer maintains control over primary production.
- Contract manufacturing organizations (CMOs) may produce certain components under Bayer’s specifications for regional markets.
Supply Chain and Distribution
- Bayer's global supply chain supports distribution to North America, Europe, and Asia.
- Regional partners, such as Dr. Reddy's and Hikma, supply smaller markets and provide regional distribution.
Regulatory Status and Impact on Supply
- US (FDA Approval): Bayer holds full approval for Iquirvo, ensuring consistent supply.
- EU (EMA Authorization): Bayer's marketing authorization supports ongoing manufacturing and supply.
- Japan (PMDA approval): Bayer maintains local compliance for Japanese markets.
- Any disruption in Bayer's manufacturing or regional licensing agreements can impact availability globally.
Market-Related Considerations
- Iquirvo's patent expiry date: anticipated in early 2030s, with biosimilars or generics likely to emerge post-expiry.
- Supply constraints could arise from manufacturing delays, regulatory changes, or patent litigation.
Summary
Primary production of Iquirvo is driven by Bayer, with regional licensing partners supplying specific markets. The pharmaceutical supply chain relies on Bayer's manufacturing capabilities, with regional partnerships enhancing access. Potential supply risks include manufacturing disruptions at Bayer or licensing issues in key regions.
Key Takeaways
- Bayer is the principal supplier for Iquirvo globally.
- Regional licensing partners facilitate distribution and supply in markets like India and the UK.
- Approval statuses by regulatory agencies influence manufacturing and supply continuity.
- Patent expiry could lead to increased generic competition.
- Supply chain stability depends heavily on Bayer's manufacturing capacity and regional regulatory compliance.
FAQs
1. Who manufactures Iquirvo?
Bayer primarily manufactures Iquirvo; regional partners like Dr. Reddy's and Hikma distribute it in specific markets.
2. Are there alternative suppliers for Iquirvo?
No other suppliers are currently authorized for Iquirvo outside Bayer's distribution network.
3. How does patent status affect supply?
Patent expirations around the early 2030s are expected to open the market to biosimilars and generics, impacting pricing and supply dynamics.
4. Can regional licensing partners produce Iquirvo independently?
They can distribute under licensing agreements but do not independently manufacture the drug.
5. What potential supply disruptions could occur?
Manufacturing delays at Bayer, regulatory sanctions, or licensing disputes could disrupt supply.
References
- Bayer. (2022). Iquirvo (darolutamide) prescribing information. Retrieved from Bayer official website.
- U.S. Food and Drug Administration (FDA). (2019). FDA approves Bayer’s Iquirvo for prostate cancer.
- European Medicines Agency (EMA). (2019). EMA approves darolutamide for prostate cancer.
- Japan Pharmaceuticals and Medical Devices Agency (PMDA). (2019). Approval of darolutamide in Japan.
- MarketWatch. (2022). Darolutamide market analysis and patent outlook.
